Renaissance Technologies
ELTX icon

Renaissance Technologies’s Elicio Therapeutics ELTX Stock Holding History

Renaissance Technologies’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$292K Buy
+160,550
New +$445K ﹤0.01% 2786
2026
Q2 		– Sell
-121,631
Closed -$1.3M – 3303
2026
Q1 		$1.3M Buy
121,631
+93,520
+333% +$903K ﹤0.01% 2131
2025
Q4 		$224K Sell
28,111
-20,560
-42% -$187K ﹤0.01% 2859
2025
Q3 		$532K Buy
+48,671
New +$493K ﹤0.01% 2762
2024
Q2 		– Sell
-11,761
Closed -$89K – 3601
2024
Q1 		$89K Sell
11,761
-4,705
-29% -$23.6K ﹤0.01% 3394
2023
Q4 		$137K Buy
+16,466
New +$107K ﹤0.01% 3230
2023
Q2 		– Sell
-9,302
Closed -$54K – 4014
2023
Q1 		$54K Sell
9,302
-2,868
-24% -$19.1K ﹤0.01% 3643
2022
Q4 		$99K Sell
12,170
-8,728
-42% -$79.3K ﹤0.01% 3619
2022
Q3 		$192K Sell
20,898
-452
-2% -$4.72K ﹤0.01% 3399
2022
Q2 		$243K Sell
21,350
-1,020
-5% -$16.3K ﹤0.01% 3562
2022
Q1 		$474K Buy
22,370
+3,260
+17% +$73.6K ﹤0.01% 3230
2021
Q4 		$554K Buy
+19,110
New +$966K ﹤0.01% 3027

Other funds holding ELTX

Shah Capital Management
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Renaissance Technologies's ELTX Position: Q3 2026 in Review

Renaissance Technologies opened a new position in Elicio Therapeutics (ELTX) in Q3 2026: 160,550 shares worth $292K. The stake represents ﹤0.01% of the portfolio and ranks #2786 among its holdings. This is a return to the name: Renaissance Technologies previously reported a position in ELTX as recently as Q1 2026.

Renaissance Technologies first reported a position in ELTX in Q4 2021 and has held it in 12 quarters since. The position peaked at $1.3M in Q1 2026. 57 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

  • Renaissance Technologies held 160,550 shares of Elicio Therapeutics worth $292K as of Q3 2026.
  • Elicio Therapeutics was a new Renaissance Technologies position in Q3 2026.
  • Elicio Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q3 2026, its #2786 holding.
  • Renaissance Technologies first reported a position in Elicio Therapeutics in Q4 2021 and has held it in 12 quarters since.
  • Renaissance Technologies's Elicio Therapeutics position peaked at $1.3M in Q1 2026.
  • 57 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.